The Filing Desk

Celldex Therapeutics vs Shattuck Labs

Celldex Therapeutics CLDX · Shattuck Labs STTK · Biotechnology

Celldex Therapeutics reported revenue of $2 million in fiscal 2025, 1.5 times Shattuck Labs' $1 million in fiscal 2025. Celldex Therapeutics' revenue fell 78.0% in its latest year, and Shattuck Labs' fell 82.5%. Celldex Therapeutics had an operating margin of -18599.8%, against -5150.8% at Shattuck Labs. Free cash flow was −$214 million at Celldex Therapeutics and −$40 million at Shattuck Labs.

Side by side

Celldex TherapeuticsShattuck Labs
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$1M
Revenue growth−78.0%−82.5%
Revenue growth a year, last 5 years−27.3%−36.8%
Gross margin87.1%—
Operating margin−18,599.8%−5,150.8%
Net margin−16,748.0%−4,880.9%
Free cash flow−$214M−$40M
Free cash flow margin−13,829.1%−3,995.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.1%37.1%
Last close$28.83$4.65
P/E at the last close——
Insider trades, last 12 monthssold $121,231—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Celldex TherapeuticsShattuck Labs
Operating margin
Percent of revenue
Celldex TherapeuticsShattuck Labs
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Celldex TherapeuticsShattuck Labs

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celldex Therapeutics and Shattuck Labs pages.